Trial Profile

Phase 2 trial assessing CyPep 1 in Adrenocortical Carcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Apr 2025 According to Cytovation media release, the study is due to start in late 2025 and with first clinical readouts expected in 2026.
23 Apr 2025 According to Cytovation media release, the company announced that it has raised NOK62 million (US$6m) largely from existing investors, led by Sandwater. These funds will be used to advance this study.
23 Jan 2025 According to Cytovation media release, Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC). Cancer Research UK's Centre for Drug Development to run the trial at sites in UK, and others across Europe. The Norwegian Cancer Society to provide co-funding to support the trial. Cytovation will be responsible for providing CY-101 for the clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com